Alex Yashchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex Yashchenko has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Kurt A. Zimmerman
Division of Nephrology, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
5 shared publications - Audrey M. Cordova
Department of Internal Medicine, Division of Nephrology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, 73104, USA
2 shared publications - Bibi Maryam
Department of Internal Medicine, Division of Nephrology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, 73104, USA
2 shared publications - Bradley K. Yoder
University of Alabama at Birmingham
2 shared publications Isabella G. Darby
Department of Internal Medicine, Division of Nephrology, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, 73104, USA
2 shared publications- Katharina Hopp
Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (17)
A cross-model single-cell atlas reveals conserved involvement of osteopontin in polycystic kidney disease
Polycystic kidney disease (PKD) arises from mutations in cilia-associated genes, such as PKD1 and PKD2 , expressed in renal epithelial cells, leading to progressive kidney dysfunction and end-stage kidney disease. Patients with PKD exhibit significant heterogeneity in disease progression, largely due to genetic and environmental modifiers. Like patients, mouse models of PKD also exhibit significant heterogeneity with regards to the gene mutated, age of disease onset, and rate of disease progression. To elucidate the cellular and molecular consequences of these variables, we constructed an integrated single-cell RNA sequencing (scRNA-seq) atlas across mouse models of PKD, mapping changes in cell type composition, gene expression, and intercellular signaling networks across the whole atlas and within individual models. Across models, scRNA-seq data revealed increased Spp1 (osteopontin) expression and signaling from PKD-enriched clusters. Global deletion of Spp1 in Pkd1 RC/RC mice resulted in a modest reduction in cyst severity and improved kidney function. From these studies, we created a freely available, searchable website (https://bmblx.bmi.osumc.edu/scPKD/) that can be used to identify cross- and intra-model changes in gene expression, guiding researchers to new therapeutic targets for treating PKD.
- 23 July 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (17)
Open AccessA cross-model single-cell atlas reveals conserved involvement of osteopontin in polycystic kidney disease
Polycystic kidney disease (PKD) arises from mutations in cilia-associated genes, such as PKD1 and PKD2 , expressed in renal epithelial cells, leading to progressive kidney dysfunction and end-stage kidney disease. Patients with PKD exhibit significant heterogeneity in disease progression, largely due to genetic and environmental modifiers. Like patients, mouse models of PKD also exhibit significant heterogeneity with regards to the gene mutated, age of disease onset, and rate of disease progression. To elucidate the cellular and molecular consequences of these variables, we constructed an integrated single-cell RNA sequencing (scRNA-seq) atlas across mouse models of PKD, mapping changes in cell type composition, gene expression, and intercellular signaling networks across the whole atlas and within individual models. Across models, scRNA-seq data revealed increased Spp1 (osteopontin) expression and signaling from PKD-enriched clusters. Global deletion of Spp1 in Pkd1 RC/RC mice resulted in a modest reduction in cyst severity and improved kidney function. From these studies, we created a freely available, searchable website (https://bmblx.bmi.osumc.edu/scPKD/) that can be used to identify cross- and intra-model changes in gene expression, guiding researchers to new therapeutic targets for treating PKD.
- Open Access
- 7 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 1956-1967
The Kinetics and Mechanism of Niche Filling in Healthy and Cystic Mice
Key Points: The rate and mechanism of kidney-resident macrophage niche filling differs between healthy and cystic mice. An incompletely filled kidney-resident macrophage niche is associated with worsened polycystic kidney disease outcomes. Background: Previous data indicate that bone marrow–derived Ly6c hi monocytes can become tissue-resident macrophages when the niche is available. However, the balance between monocyte recruitment and tissue-resident macrophage self-proliferation following partial depletion is unclear. Methods: We investigated the kinetics and mechanism of kidney-resident macrophage (KRM) niche filling in healthy mice and in a mouse model of autosomal dominant polycystic kidney disease after partial depletion with liposomal clodronate. Results: Our data indicate that healthy mice efficiently refilled their KRM niche through monocyte-dependent recruitment, engraftment, and differentiation while cystic mice relied preferentially on in situ KRM self-proliferation for niche filling. Furthermore, we found sex-specific differences in niche-filling capacity in cystic mice as female, but not male, mice were unable to completely fill their niche 90 days postdepletion. The inability of cystic female mice to fill the niche following depletion was likely due to their reduced ability to recruit monocytes and convert them into KRM. Phenotypically, delayed KRM niche filling was associated with worsened outcomes including increased cystic index and kidney fibrosis as well as worsened kidney function. Conclusions: Collectively, our data demonstrate that sex and disease status affect the kinetics and mechanism of niche filling in the kidney.
- 7 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 1956-1967
Open AccessThe Kinetics and Mechanism of Niche Filling in Healthy and Cystic Mice
Key Points: The rate and mechanism of kidney-resident macrophage niche filling differs between healthy and cystic mice. An incompletely filled kidney-resident macrophage niche is associated with worsened polycystic kidney disease outcomes. Background: Previous data indicate that bone marrow–derived Ly6c hi monocytes can become tissue-resident macrophages when the niche is available. However, the balance between monocyte recruitment and tissue-resident macrophage self-proliferation following partial depletion is unclear. Methods: We investigated the kinetics and mechanism of kidney-resident macrophage (KRM) niche filling in healthy mice and in a mouse model of autosomal dominant polycystic kidney disease after partial depletion with liposomal clodronate. Results: Our data indicate that healthy mice efficiently refilled their KRM niche through monocyte-dependent recruitment, engraftment, and differentiation while cystic mice relied preferentially on in situ KRM self-proliferation for niche filling. Furthermore, we found sex-specific differences in niche-filling capacity in cystic mice as female, but not male, mice were unable to completely fill their niche 90 days postdepletion. The inability of cystic female mice to fill the niche following depletion was likely due to their reduced ability to recruit monocytes and convert them into KRM. Phenotypically, delayed KRM niche filling was associated with worsened outcomes including increased cystic index and kidney fibrosis as well as worsened kidney function. Conclusions: Collectively, our data demonstrate that sex and disease status affect the kinetics and mechanism of niche filling in the kidney.
- 15 August 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (5) , 664-681
Vagal Stimulation Rescues HFpEF by Altering Cardiac Resident Macrophage Function
BACKGROUND: We previously showed in a rat model of heart failure with preserved ejection fraction (HFpEF) that transcutaneous vagus nerve stimulation (tVNS) reduced cardiac fibrosis and inflammation. However, macrophage-mediated mechanisms through which tVNS rescues cardiac function remain poorly understood. METHODS: We induced HFpEF in 8-week-old mice by a combination of a high-fat diet and l -NG-nitro arginine methyl ester for 5 weeks, followed by 4 weeks of tVNS or sham stimulation. At this time, we analyzed cardiac function by echocardiography and immune cell numbers by single-cell RNA sequencing and flow cytometry. RESULTS: Our data demonstrate that HFpEF mice exhibited diastolic dysfunction, left ventricular hypertrophy, and fibrosis, consistent with HFpEF, and that tVNS significantly improved HFpEF severity. Analysis of merged single-cell RNA sequencing data from control, HFpEF+sham, and HFpEF+tVNS mice showed that HFpEF was associated with the accumulation of Spp1 -expressing CCR2 (C-C chemokine receptor type 2) + cardiac resident macrophages (CRM). Furthermore, treatment with tVNS reduced the number of CCR2 + CRM and the expression of Spp1 while also inducing the expression of Igf1 in TLF + (Timd4 + [T-cell immunoglobulin and mucin domain containing 4 + ]/Lyve1 + [Lymphatic vessel endothelial hyaluronan receptor 1 + ]/Folr2 + [Folate receptor 2 + ]) and MHC2 + (Major histocompatibility complex 2 + ) CRM. Global deletion of Spp1 or blockade of CCR2 + CRM recruitment improved HFpEF, whereas TLF + /MHC2 + specific deletion of Igf1 reversed the protective effect of tVNS on HFpEF. The benefits of tVNS were also abolished in the setting of disrupted acetylcholine/α7nAChR (α7 nicotinic acetylcholine receptor) signaling, either via pharmacological inhibition of α7nAChR or choline acetyltransferase deletion in CD4 + (cluster of differentiation) T cells. CONCLUSIONS: Collectively, our data indicate that tVNS improves HFpEF by reducing Spp1 expressing CCR2 + CRM and inducing expression of proreparative Igf1 in TLF + /MHC2 + CRM. These effects are mediated through cholinergic signaling, highlighting a neuroimmune pathway in HFpEF.
- 15 August 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (5) , 664-681
Vagal Stimulation Rescues HFpEF by Altering Cardiac Resident Macrophage Function
BACKGROUND: We previously showed in a rat model of heart failure with preserved ejection fraction (HFpEF) that transcutaneous vagus nerve stimulation (tVNS) reduced cardiac fibrosis and inflammation. However, macrophage-mediated mechanisms through which tVNS rescues cardiac function remain poorly understood. METHODS: We induced HFpEF in 8-week-old mice by a combination of a high-fat diet and l -NG-nitro arginine methyl ester for 5 weeks, followed by 4 weeks of tVNS or sham stimulation. At this time, we analyzed cardiac function by echocardiography and immune cell numbers by single-cell RNA sequencing and flow cytometry. RESULTS: Our data demonstrate that HFpEF mice exhibited diastolic dysfunction, left ventricular hypertrophy, and fibrosis, consistent with HFpEF, and that tVNS significantly improved HFpEF severity. Analysis of merged single-cell RNA sequencing data from control, HFpEF+sham, and HFpEF+tVNS mice showed that HFpEF was associated with the accumulation of Spp1 -expressing CCR2 (C-C chemokine receptor type 2) + cardiac resident macrophages (CRM). Furthermore, treatment with tVNS reduced the number of CCR2 + CRM and the expression of Spp1 while also inducing the expression of Igf1 in TLF + (Timd4 + [T-cell immunoglobulin and mucin domain containing 4 + ]/Lyve1 + [Lymphatic vessel endothelial hyaluronan receptor 1 + ]/Folr2 + [Folate receptor 2 + ]) and MHC2 + (Major histocompatibility complex 2 + ) CRM. Global deletion of Spp1 or blockade of CCR2 + CRM recruitment improved HFpEF, whereas TLF + /MHC2 + specific deletion of Igf1 reversed the protective effect of tVNS on HFpEF. The benefits of tVNS were also abolished in the setting of disrupted acetylcholine/α7nAChR (α7 nicotinic acetylcholine receptor) signaling, either via pharmacological inhibition of α7nAChR or choline acetyltransferase deletion in CD4 + (cluster of differentiation) T cells. CONCLUSIONS: Collectively, our data indicate that tVNS improves HFpEF by reducing Spp1 expressing CCR2 + CRM and inducing expression of proreparative Igf1 in TLF + /MHC2 + CRM. These effects are mediated through cholinergic signaling, highlighting a neuroimmune pathway in HFpEF.
- 1 April 2022
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (4) , 747-768
A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice
Background: Inducible disruption of cilia-related genes in adult mice results in slowly progressive cystic disease, which can be greatly accelerated by renal injury. Methods: To identify in an unbiased manner modifier cells that may be influencing the differential rate of cyst growth in injured versus non-injured cilia mutant kidneys at a time of similar cyst severity, we generated a single-cell atlas of cystic kidney disease. We conducted RNA-seq on 79,355 cells from control mice and adult-induced conditional Ift88 mice (hereafter referred to as cilia mutant mice) that were harvested approximately 7 months post-induction or 8 weeks post 30-minute unilateral ischemia reperfusion injury. Results: Analyses of single-cell RNA-seq data of CD45+ immune cells revealed that adaptive immune cells differed more in cluster composition, cell proportion, and gene expression than cells of myeloid origin when comparing cystic models with one another and with non-cystic controls. Surprisingly, genetic deletion of adaptive immune cells significantly reduced injury-accelerated cystic disease but had no effect on cyst growth in non-injured cilia mutant mice, independent of the rate of cyst growth or underlying genetic mutation. Using NicheNet, we identified a list of candidate cell types and ligands that were enriched in injured cilia mutant mice compared with aged cilia mutant mice and non-cystic controls that may be responsible for the observed dependence on adaptive immune cells during injury-accelerated cystic disease. Conclusions: Collectively, these data highlight the diversity of immune cell involvement in cystic kidney disease.
- 1 April 2022
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (4) , 747-768
A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice
Background: Inducible disruption of cilia-related genes in adult mice results in slowly progressive cystic disease, which can be greatly accelerated by renal injury. Methods: To identify in an unbiased manner modifier cells that may be influencing the differential rate of cyst growth in injured versus non-injured cilia mutant kidneys at a time of similar cyst severity, we generated a single-cell atlas of cystic kidney disease. We conducted RNA-seq on 79,355 cells from control mice and adult-induced conditional Ift88 mice (hereafter referred to as cilia mutant mice) that were harvested approximately 7 months post-induction or 8 weeks post 30-minute unilateral ischemia reperfusion injury. Results: Analyses of single-cell RNA-seq data of CD45+ immune cells revealed that adaptive immune cells differed more in cluster composition, cell proportion, and gene expression than cells of myeloid origin when comparing cystic models with one another and with non-cystic controls. Surprisingly, genetic deletion of adaptive immune cells significantly reduced injury-accelerated cystic disease but had no effect on cyst growth in non-injured cilia mutant mice, independent of the rate of cyst growth or underlying genetic mutation. Using NicheNet, we identified a list of candidate cell types and ligands that were enriched in injured cilia mutant mice compared with aged cilia mutant mice and non-cystic controls that may be responsible for the observed dependence on adaptive immune cells during injury-accelerated cystic disease. Conclusions: Collectively, these data highlight the diversity of immune cell involvement in cystic kidney disease.
- 22 June 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 101 (10) , 1382-1393
Early infiltrating macrophage subtype correlates with late-stage phenotypic outcome in a mouse model of hepatorenal fibrocystic disease
- 22 June 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 101 (10) , 1382-1393
Early infiltrating macrophage subtype correlates with late-stage phenotypic outcome in a mouse model of hepatorenal fibrocystic disease